Publications

Ena Respiratory

The COPD Foundation’s COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral Respiratory Infections

Read more

Safety and Tolerability of the Toll-Like Receptor (TLR)2/6 Agonist INNA-051 in Healthy Adults

Read more

TLR-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. JCI Insight. 2021

Read more

Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. EBioMedicine. 2020

Read more

TLR2-mediated innate immune priming boosts lung anti-viral immunity. European Respiratory Journal. 2020

Read more

Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys. Front Immunol. 2015

Read more

Reducing the impact of influenza-associated secondary pneumococcal infections. Immunol. Cell Biol. 2015

Read more

Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol. Pharm. 2012

Read more